(26.06.2020)

Separately, Gilead also provided updates on its production plans for the drug, noting that it expects to have over two million Remdesivir treatment courses manufactured by the end of 2020, with the number rising further over 2021, as it optimizes the manufacturing process.

For more details on the stock price and fundamental performance of some of the key U.S. listed companies developing coronavirus therapeutics, view our theme of Covid-19 Treatment Stocks.